Hansa Biopharma AB (publ) (HNSBF)
USD 2.83
(0.0%)
USD 2.83
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 859.44 Million SEK | 24.27% |
| 2022 | 692.16 Million SEK | 24.04% |
| 2021 | 558.03 Million SEK | 29.72% |
| 2020 | 430.17 Million SEK | 19.46% |
| 2019 | 360.09 Million SEK | 47.45% |
| 2018 | 244.22 Million SEK | 36.18% |
| 2017 | 179.34 Million SEK | 58.01% |
| 2016 | 113.49 Million SEK | 59.91% |
| 2015 | 70.97 Million SEK | 143.24% |
| 2014 | 29.18 Million SEK | 53.19% |
| 2013 | 19.04 Million SEK | -13.07% |
| 2012 | 21.91 Million SEK | -20.2% |
| 2011 | 27.46 Million SEK | 12.36% |
| 2010 | 24.44 Million SEK | 30.53% |
| 2009 | 18.72 Million SEK | 16.96% |
| 2008 | 16 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 190.71 Million SEK | -10.98% |
| 2024 Q3 | 154.21 Million SEK | -12.12% |
| 2024 Q2 | 175.48 Million SEK | -7.99% |
| 2023 Q3 | 208.33 Million SEK | -15.44% |
| 2023 Q4 | 214.24 Million SEK | 2.83% |
| 2023 FY | 860.13 Million SEK | 24.27% |
| 2023 Q1 | 196.89 Million SEK | 23.05% |
| 2023 Q2 | 246.38 Million SEK | 25.14% |
| 2022 FY | 692.16 Million SEK | 24.04% |
| 2022 Q2 | 189.15 Million SEK | 22.77% |
| 2022 Q3 | 188.94 Million SEK | -0.11% |
| 2022 Q4 | 160 Million SEK | -15.31% |
| 2022 Q1 | 154.06 Million SEK | -7.82% |
| 2021 FY | 558.03 Million SEK | 29.72% |
| 2021 Q4 | 167.13 Million SEK | 14.95% |
| 2021 Q3 | 145.39 Million SEK | 8.05% |
| 2021 Q2 | 134.55 Million SEK | 21.28% |
| 2021 Q1 | 110.95 Million SEK | -1.04% |
| 2020 Q1 | 91.81 Million SEK | -15.83% |
| 2020 FY | 430.17 Million SEK | 19.46% |
| 2020 Q3 | 123.92 Million SEK | 21.1% |
| 2020 Q2 | 102.33 Million SEK | 11.46% |
| 2020 Q4 | 112.11 Million SEK | -9.53% |
| 2019 Q4 | 109.08 Million SEK | 16.5% |
| 2019 FY | 360.09 Million SEK | 47.45% |
| 2019 Q1 | 73.19 Million SEK | -4.32% |
| 2019 Q2 | 84.17 Million SEK | 15.0% |
| 2019 Q3 | 93.63 Million SEK | 11.24% |
| 2018 Q3 | 60.93 Million SEK | 2.21% |
| 2018 Q1 | 47.16 Million SEK | -5.53% |
| 2018 Q2 | 59.61 Million SEK | 26.41% |
| 2018 FY | 244.22 Million SEK | 36.18% |
| 2018 Q4 | 76.5 Million SEK | 25.55% |
| 2017 Q3 | 38.05 Million SEK | -16.43% |
| 2017 Q4 | 49.91 Million SEK | 31.16% |
| 2017 FY | 179.34 Million SEK | 58.01% |
| 2017 Q1 | 45.82 Million SEK | 32.98% |
| 2017 Q2 | 45.54 Million SEK | -0.62% |
| 2016 Q2 | 31.16 Million SEK | 52.5% |
| 2016 Q4 | 34.46 Million SEK | 25.57% |
| 2016 FY | 113.49 Million SEK | 59.91% |
| 2016 Q3 | 27.44 Million SEK | -11.94% |
| 2016 Q1 | 20.43 Million SEK | 7.77% |
| 2015 FY | 70.97 Million SEK | 143.24% |
| 2015 Q4 | 18.96 Million SEK | 31.16% |
| 2015 Q3 | 14.45 Million SEK | -37.22% |
| 2015 Q2 | 23.02 Million SEK | 58.4% |
| 2015 Q1 | 14.53 Million SEK | 25.66% |
| 2014 Q2 | 5.18 Million SEK | -29.51% |
| 2014 Q4 | 11.56 Million SEK | 113.39% |
| 2014 Q1 | 7.35 Million SEK | 3.65% |
| 2014 FY | 29.18 Million SEK | 53.19% |
| 2014 Q3 | 5.42 Million SEK | 4.59% |
| 2013 FY | 19.04 Million SEK | -13.07% |
| 2013 Q2 | 2.42 Million SEK | 0.0% |
| 2013 Q3 | 7.09 Million SEK | 192.54% |
| 2013 Q4 | 7.09 Million SEK | 0.0% |
| 2012 FY | 21.91 Million SEK | -20.2% |
| 2011 FY | 27.46 Million SEK | 12.36% |
| 2010 FY | 24.44 Million SEK | 30.53% |
| 2009 FY | 18.72 Million SEK | 16.96% |
| 2008 FY | 16 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -890.317% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -17375.848% |
| SQZ Biotechnologies Company | 85.61 Million USD | -903.804% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -2808.155% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -2206.889% |
| Mesoblast Limited | 5.9 Million USD | -14461.962% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -57124.021% |
| Genus plc | 147.7 Million USD | -481.887% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -9689.544% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -63963.971% |
| Marizyme, Inc. | 19.23 Million USD | -4367.019% |
| ContraFect Corporation | 56.88 Million USD | -1410.744% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -10206.356% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -19394.465% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -58019.752% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -29371.116% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -30700.611% |
| MultiCell Technologies, Inc. | 567.42 USD | -151465657.287% |
| Accustem Sciences Inc. | 3.74 Million USD | -22840.493% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -899.997% |
| EV Biologics, Inc. | 531.96 Thousand USD | -161461.728% |
| Q BioMed Inc. | 3.43 Million USD | -24908.439% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -3377.431% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -220516.532% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -32609.412% |
| Biomind Labs Inc. | 994.18 Thousand USD | -86347.652% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | -281.145% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -12693.169% |
| Skye Bioscience, Inc. | 13.54 Million USD | -6243.929% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -41850.744% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 3437888.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -16945.607% |
| IMV Inc. | 37.7 Million USD | -2179.143% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -5268.109% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -46733.924% |
| GB Sciences, Inc. | 1.42 Million USD | -60402.749% |
| Alpha Cognition Inc. | 9.7 Million USD | -8755.165% |
| HST Global, Inc. | 140.9 Thousand USD | -609839.18% |
| CSL Limited | 3.44 Billion USD | 75.081% |
| Halberd Corporation | 74.84 Thousand USD | -1148248.521% |
| Enzolytics Inc. | 2.17 Million USD | -39333.092% |
| Resverlogix Corp. | 12.71 Million USD | -6660.911% |
| Affymax, Inc. | 39.38 Million USD | -2082.113% |
| SYBLEU INC | 160.87 Thousand USD | -534129.469% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -23441.933% |
| argenx SE | 1.53 Billion USD | 43.956% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -1396.252% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -82222.51% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -54317.595% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -25140.89% |
| AVAX Technologies, Inc. | 7.31 Million USD | -11656.716% |
| Zenith Capital Corp. | 8.94 Million USD | -9510.276% |
| Genscript Biotech Corporation | 825.34 Million USD | -4.132% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -4933296.476% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -34903.505% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -501008.98% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -765.243% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -48741.152% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -43481.754% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -45998.521% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -7808.779% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -44641.752% |
| BioStem Technologies, Inc. | 22.97 Million USD | -3640.824% |
| ONE Bio Corp. | 6.44 Million USD | -13237.39% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -473463.655% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -64257.275% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -76301.401% |
| Agentix Corp. | 1.37 Million USD | -62553.052% |
| LadRx Corporation | 3.81 Million USD | -22447.065% |
| Cell Source, Inc. | 4.32 Million USD | -19770.017% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -206756.905% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -92963.096% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -92963.096% |
| NovAccess Global Inc. | 2.46 Million USD | -34741.114% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -35636.823% |
| Itoco Inc. | 919.14 Thousand USD | -93405.254% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -20177.561% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -76704.915% |
| Kadimastem Ltd | 2.41 Million USD | -35560.044% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -328276.623% |
| CytoDyn Inc. | 18.05 Million USD | -4659.37% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -3414604.597% |
| Mobile Lads Corp. | 554.54 Thousand USD | -154882.093% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -390419.27% |
| Qrons Inc. | 643.67 Thousand USD | -133421.471% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -60433.303% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -38442.316% |
| Rebus Holdings, Inc. | 664 Thousand USD | -129334.789% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -47218.039% |
| International Stem Cell Corporation | 5.27 Million USD | -16205.198% |
| Bioxytran, Inc. | 3.82 Million USD | -22397.747% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1632526.04% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -4224680.023% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -2269.842% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -53017.862% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -116698.875% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -27526.069% |
| Neutra Corp. | 243.82 Thousand USD | -352390.967% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -4823.223% |
| PureTech Health plc | 144.59 Million USD | -494.374% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -4094.493% |
| IXICO plc | 4.7 Million USD | -18158.912% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -9669.774% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -629.904% |
| CSL Limited | 3.89 Billion USD | 77.923% |
| Cellectis S.A. | 97.32 Million USD | -783.114% |